DALACIN CREAM Vaginal Cream (2021)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Dalacin Cream 2%.
Qualitative and quantitative composition
Each gram of cream contains clindamycin phosphate equivalent to 20 mg or 2.0% w/w clindamycin. Each applicator full of 5 grams of vaginal cream contains approximately 100 mg of clindamycin phosphate. ...
Pharmaceutical form
Vaginal Cream. White, semi-solid.
Therapeutic indications
Antibiotic for the treatment of bacterial vaginosis.
Posology and method of administration
Posology One applicator full intravaginally at bedtime for 7 consecutive days. In patients for whom a shorter treatment course is desirable, a 3 day regimen has been shown to be effective. Paediatric population ...
Contraindications
Dalacin Cream is contra-indicated in patients with a history of hypersensitivity to clindamycin, lincomycin, or to any of the excipients listed in section 6.1. Dalacin Cream 2% is also contraindicated ...
Special warnings and precautions for use
Before or after initiation of therapy with clindamycin, other infections including <em>Trichomonas vaginalis</em>, <em>Candida albicans</em>, <em>Chlamydia trachomatis</em> and <em>gonococcal</em> infections ...
Interaction with other medicinal products and other forms of interaction
Systemic clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving ...
Fertility, pregnancy and lactation
Pregnancy Use of clindamycin is not recommended during the first trimester, as there are no adequate and well-controlled studies in pregnant women over this period. In clinical trials, intravaginal use ...
Effects on ability to drive and use machines
The effect of clindamycin on the ability to drive or operate machinery has not been systematically evaluated.
Undesirable effects
The table below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency. Adverse reactions identified from post-marketing ...
Overdose
There are no reports of overdose with clindamycin. Vaginally applied clindamycin phosphate vaginal cream 2% can be absorbed in sufficient amounts to produce systemic effects. In the event of overdosage, ...
Pharmacodynamic properties
<b>Pharmacotherapeutic group:</b> Gynaecological anti-infectives and antiseptics <b>ATC Code:</b> G01AA10 Mechanism of action Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis ...
Pharmacokinetic properties
Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered to 6 healthy female volunteers for 7 days, approximately 4% (range 0.6% to 11%) of the administered ...
Preclinical safety data
Impairment of fertility Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m²) revealed no effects on fertility or mating ability. Pregnancy In oral ...
List of excipients
Sorbitan stearate Polysorbate 60 Propylene glycol (E1520) Stearic acid Cetostearyl alcohol Cetyl palmitate Liquid paraffin Benzyl alcohol (E1519) Water
Incompatibilities
Not applicable.
Shelf life
2 years.
Special precautions for storage
Do not store above 25°C. Do not freeze.
Nature and contents of container
Laminate tube (consisting of LMDPE and aluminium foil) with polypropylene cap containing 7.8 g, 20 g or 40 g cream, packed in cardboard carton, together with a leaflet. Not all pack sizes may be marketed. ...
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Marketing authorization number(s)
PL 00057/0960
Date of first authorization / renewal of the authorization
Date of first authorisation: 27 April 1993 Date of latest renewal 7<sup>th</sup> August 2009
Date of revision of the text
05/2021
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: